https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Zanubrutinib Linked to Lower Infection Risk Than Venetoclax Plus Obinutuzumab in Real-World CLL/SLL Study

Zanubrutinib Linked to Lower Infection Risk Than Venetoclax Plus Obinutuzumab in Real-World CLL/SLL Study

New research highlights the lower infection risk with zanubrutinib compared to venetoclax in CLL/SLL treatment, offering safer options for patients.

administrator

Related Articles